Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter

Executive Summary

In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.

You may also be interested in...



Final Development Stage For Prolia Reflects Amgen's Eye On Advertising

Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage

Final Development Stage For Prolia Reflects Amgen's Eye On Advertising

Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage

Final Development Stage For Prolia Reflects Amgen's Eye On Advertising

Biotech's roll-out of clinical data on the RANK ligand inhibitor no longer is studies that supported the initial application but studies focused on particular claims or comparative advantages that will improve Prolia's commercial outlook.

Related Content

Topics

UsernamePublicRestriction

Register

PS050617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel